10x Genomics (TXG) Change in Receivables (2018 - 2026)

10x Genomics (TXG) has 9 years of Change in Receivables data on file, last reported at -$8.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 77.41% year-over-year to -$8.0 million; the trailing twelve-month figure through Mar 2026 stood at -$14.0 million (up 63.96% YoY), and the FY2025 full-year result was -$41.3 million, down 53.29% from the prior year.
• Change in Receivables eased to -$8.0 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $20.6 million in Q4 2022 to a low of -$35.3 million in Q1 2025.
• A 5-year average of -$2.7 million and a median of -$297000.0 in 2022 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables jumped 3383.84% in 2023 and sank 2024.59% in 2025, its largest moves.
• Tracing TXG's Change in Receivables over 5 years: stood at $20.6 million in 2022, then slumped by 46.78% to $11.0 million in 2023, then sank by 60.18% to $4.4 million in 2024, then decreased by 26.04% to $3.2 million in 2025, then tumbled by 346.91% to -$8.0 million in 2026.
• Business Quant data shows TXG's Change in Receivables at -$8.0 million in Q1 2026, $3.2 million in Q4 2025, and -$6.6 million in Q3 2025.